ID   UBA7_HUMAN              Reviewed;        1012 AA.
AC   P41226; Q9BRB2;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   18-JUN-2025, entry version 216.
DE   RecName: Full=Ubiquitin-like modifier-activating enzyme 7;
DE            Short=Ubiquitin-activating enzyme 7;
DE            EC=6.2.1.- {ECO:0000250|UniProtKB:Q9DBK7};
DE   AltName: Full=D8;
DE   AltName: Full=Ubiquitin-activating enzyme E1 homolog;
GN   Name=UBA7 {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:12471};
GN   Synonyms=UBE1L, UBE2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=B-cell;
RX   PubMed=8327486; DOI=10.1073/pnas.90.13.6071;
RA   Kok K., Hofstra R., Pilz A., van den Berg A., Terpstra P., Buys C.H.C.M.,
RA   Carritt B.;
RT   "A gene in the chromosomal region 3p21 with greatly reduced expression in
RT   lung cancer is similar to the gene for ubiquitin-activating enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6071-6075(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7734949;
RA   Kok K., Van den Berg A., Veldhuis P.M., Franke M., Terpstra P.,
RA   Buys C.H.C.M.;
RT   "The genomic structure of the human UBE1L gene.";
RL   Gene Expr. 4:163-175(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-17.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 973-987, INTERACTION WITH G1P2, AND PATHWAY.
RX   PubMed=11157743; DOI=10.1093/emboj/20.3.362;
RA   Yuan W., Krug R.M.;
RT   "Influenza B virus NS1 protein inhibits conjugation of the interferon
RT   (IFN)-induced ubiquitin-like ISG15 protein.";
RL   EMBO J. 20:362-371(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=16254333; DOI=10.1128/jvi.79.22.13974-13983.2005;
RA   Lenschow D.J., Giannakopoulos N.V., Gunn L.J., Johnston C., O'Guin A.K.,
RA   Schmidt R.E., Levine B., Virgin H.W. IV;
RT   "Identification of interferon-stimulated gene 15 as an antiviral molecule
RT   during Sindbis virus infection in vivo.";
RL   J. Virol. 79:13974-13983(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=19073728; DOI=10.1128/jvi.01590-08;
RA   Giannakopoulos N.V., Arutyunova E., Lai C., Lenschow D.J., Haas A.L.,
RA   Virgin H.W.;
RT   "ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important for
RT   innate immune control of Sindbis virus.";
RL   J. Virol. 83:1602-1610(2009).
RN   [10]
RP   FUNCTION.
RX   PubMed=20133869; DOI=10.1073/pnas.0909144107;
RA   Zhao C., Hsiang T.Y., Kuo R.L., Krug R.M.;
RT   "ISG15 conjugation system targets the viral NS1 protein in influenza A
RT   virus-infected cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2253-2258(2010).
RN   [11]
RP   ISGYLATION.
RX   PubMed=22693631; DOI=10.1371/journal.pone.0038294;
RA   Bade V.N., Nickels J., Keusekotten K., Praefcke G.J.;
RT   "Covalent protein modification with ISG15 via a conserved cysteine in the
RT   hinge region.";
RL   PLoS ONE 7:E38294-E38294(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-266, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   FUNCTION, AND INDUCTION BY DNA DAMAGE.
RX   PubMed=27545325; DOI=10.1038/ncomms12513;
RA   Park J.H., Yang S.W., Park J.M., Ka S.H., Kim J.H., Kong Y.Y., Jeon Y.J.,
RA   Seol J.H., Chung C.H.;
RT   "Positive feedback regulation of p53 transactivity by DNA damage-induced
RT   ISG15 modification.";
RL   Nat. Commun. 7:12513-12513(2016).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL26
RP   (MICROBIAL INFECTION).
RX   PubMed=27564865; DOI=10.1371/journal.ppat.1005850;
RA   Kim Y.J., Kim E.T., Kim Y.E., Lee M.K., Kwon K.M., Kim K.I., Stamminger T.,
RA   Ahn J.H.;
RT   "Consecutive Inhibition of ISG15 Expression and ISGylation by
RT   Cytomegalovirus Regulators.";
RL   PLoS Pathog. 12:e1005850-e1005850(2016).
RN   [15]
RP   FUNCTION.
RX   PubMed=29056542; DOI=10.1016/j.meegid.2017.10.016;
RA   Zhao P., Jiang T., Zhong Z., Zhao L., Yang S., Xia X.;
RT   "Inhibition of rabies virus replication by interferon-stimulated gene 15
RT   and its activating enzyme UBA7.";
RL   Infect. Genet. Evol. 56:44-53(2017).
RN   [16]
RP   INDUCTION BY INTERFERON-ALPHA.
RX   PubMed=28035359; DOI=10.3892/ijmm.2016.2845;
RA   Zhou M.J., Chen F.Z., Chen H.C., Wan X.X., Zhou X., Fang Q., Zhang D.Z.;
RT   "ISG15 inhibits cancer cell growth and promotes apoptosis.";
RL   Int. J. Mol. Med. 39:446-452(2017).
RN   [17]
RP   FUNCTION, INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN NEC2/UL50
RP   (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=29743376; DOI=10.1128/jvi.00462-18;
RA   Lee M.K., Kim Y.J., Kim Y.E., Han T.H., Milbradt J., Marschall M.,
RA   Ahn J.H.;
RT   "Transmembrane Protein pUL50 of Human Cytomegalovirus Inhibits ISGylation
RT   by Downregulating UBE1L.";
RL   J. Virol. 92:0-0(2018).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH ROTAVIRUS PROTEIN NSP5 (MICROBIAL
RP   INFECTION).
RX   PubMed=37722521; DOI=10.1016/j.cellsig.2023.110891;
RA   Sarkar R., Patra U., Mukherjee A., Mitra S., Komoto S., Chawla-Sarkar M.;
RT   "Rotavirus circumvents the antiviral effects of protein ISGylation via
RT   proteasomal degradation of Ube1L.";
RL   Cell. Signal. 0:0-0(2023).
RN   [19]
RP   VARIANT 397-GLU--LEU-1012 DEL.
RX   PubMed=28397838; DOI=10.1038/mp.2017.60;
RA   Harripaul R., Vasli N., Mikhailov A., Rafiq M.A., Mittal K.,
RA   Windpassinger C., Sheikh T.I., Noor A., Mahmood H., Downey S., Johnson M.,
RA   Vleuten K., Bell L., Ilyas M., Khan F.S., Khan V., Moradi M., Ayaz M.,
RA   Naeem F., Heidari A., Ahmed I., Ghadami S., Agha Z., Zeinali S., Qamar R.,
RA   Mozhdehipanah H., John P., Mir A., Ansar M., French L., Ayub M.,
RA   Vincent J.B.;
RT   "Mapping autosomal recessive intellectual disability: combined microarray
RT   and exome sequencing identifies 26 novel candidate genes in 192
RT   consanguineous families.";
RL   Mol. Psychiatry 23:973-984(2018).
CC   -!- FUNCTION: E1-activating enzyme that catalyzes the covalent conjugation
CC       of the ubiquitin-like protein product of ISG15 to additional interferon
CC       stimulated proteins (ISGs) as well as other cellular proteins such as
CC       P53 in a process termed protein ISGylation (PubMed:27545325). Plays an
CC       essential role in antiviral immunity together with ISG15 by restricting
CC       the replication of many viruses including rabies virus, influenza
CC       virus, sindbis virus, rotavirus or human cytomegalovirus
CC       (PubMed:16254333, PubMed:19073728, PubMed:29056542, PubMed:29743376,
CC       PubMed:37722521). For example, ISG15 modification of influenza A
CC       protein NS1 disrupts the association of the NS1 with importin-alpha
CC       leading to NS1 nuclear import inhibition (PubMed:20133869). ISGylation
CC       of human cytomegalovirs protein UL26 regulates its stability and
CC       inhibits its activities to suppress NF-kappa-B signaling
CC       (PubMed:27564865). {ECO:0000269|PubMed:16254333,
CC       ECO:0000269|PubMed:19073728, ECO:0000269|PubMed:20133869,
CC       ECO:0000269|PubMed:27545325, ECO:0000269|PubMed:27564865,
CC       ECO:0000269|PubMed:29056542, ECO:0000269|PubMed:29743376,
CC       ECO:0000269|PubMed:37722521}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:11157743}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       proteins NEC2/UL50 and UL26; these interactions inhibit ISGylation and
CC       cause proteasomal degradation of UBA7. {ECO:0000269|PubMed:27564865,
CC       ECO:0000269|PubMed:29743376}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with rotavirus non-structural
CC       protein 5 (NSP5); this interaction promotes UBA7 proteasomal
CC       degradation. {ECO:0000269|PubMed:37722521}.
CC   -!- SUBUNIT: Monomer (By similarity). Binds and is involved in the
CC       conjugation of G1P2/ISG15. {ECO:0000250}.
CC   -!- INTERACTION:
CC       P41226; P05161: ISG15; NbExp=12; IntAct=EBI-751921, EBI-746466;
CC       P41226; Q13148: TARDBP; NbExp=3; IntAct=EBI-751921, EBI-372899;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:29743376}. Nucleus
CC       {ECO:0000269|PubMed:29743376}.
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of normal and tumor cell
CC       types, but is reduced in lung cancer cell lines.
CC   -!- INDUCTION: By DNA damage (PubMed:27545325). Upon interferon-alpha
CC       exposure (PubMed:28035359). {ECO:0000269|PubMed:27545325,
CC       ECO:0000269|PubMed:28035359}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:22693631}.
CC   -!- PTM: Ubiquitinated by RNF170. {ECO:0000269|PubMed:29743376}.
CC   -!- MISCELLANEOUS: There are two active sites within the E1 molecule,
CC       allowing it to accommodate two ubiquitin moieties at a time, with a new
CC       ubiquitin forming an adenylate intermediate as the previous one is
CC       transferred to the thiol site.
CC   -!- SIMILARITY: Belongs to the ubiquitin-activating E1 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13852; AAA75388.1; -; mRNA.
DR   EMBL; AF294032; AAG49557.1; -; Genomic_DNA.
DR   EMBL; BT007026; AAP35672.1; -; mRNA.
DR   EMBL; CH471055; EAW65023.1; -; Genomic_DNA.
DR   EMBL; BC006378; AAH06378.1; -; mRNA.
DR   CCDS; CCDS2805.1; -.
DR   RefSeq; NP_003326.2; NM_003335.2.
DR   PDB; 8OIF; EM; 3.50 A; A=1-1012.
DR   PDB; 8SE9; EM; 3.20 A; A=1-1012.
DR   PDB; 8SEA; EM; 3.40 A; A=1-1012.
DR   PDB; 8SEB; EM; 3.24 A; A=1-1012.
DR   PDB; 8SV8; EM; 3.38 A; A=1-1012.
DR   PDB; 8WWX; NMR; -; A=920-1012.
DR   PDBsum; 8OIF; -.
DR   PDBsum; 8SE9; -.
DR   PDBsum; 8SEA; -.
DR   PDBsum; 8SEB; -.
DR   PDBsum; 8SV8; -.
DR   PDBsum; 8WWX; -.
DR   AlphaFoldDB; P41226; -.
DR   EMDB; EMD-16891; -.
DR   EMDB; EMD-18589; -.
DR   EMDB; EMD-40407; -.
DR   EMDB; EMD-40408; -.
DR   EMDB; EMD-40409; -.
DR   EMDB; EMD-40782; -.
DR   SMR; P41226; -.
DR   BioGRID; 113166; 16.
DR   DIP; DIP-60526N; -.
DR   FunCoup; P41226; 605.
DR   IntAct; P41226; 10.
DR   MINT; P41226; -.
DR   STRING; 9606.ENSP00000333266; -.
DR   BindingDB; P41226; -.
DR   ChEMBL; CHEMBL2321623; -.
DR   iPTMnet; P41226; -.
DR   PhosphoSitePlus; P41226; -.
DR   BioMuta; UBA7; -.
DR   DMDM; 215273977; -.
DR   jPOST; P41226; -.
DR   MassIVE; P41226; -.
DR   PaxDb; 9606-ENSP00000333266; -.
DR   PeptideAtlas; P41226; -.
DR   ProteomicsDB; 55434; -.
DR   Pumba; P41226; -.
DR   Antibodypedia; 4219; 344 antibodies from 36 providers.
DR   DNASU; 7318; -.
DR   Ensembl; ENST00000333486.4; ENSP00000333266.3; ENSG00000182179.13.
DR   GeneID; 7318; -.
DR   KEGG; hsa:7318; -.
DR   MANE-Select; ENST00000333486.4; ENSP00000333266.3; NM_003335.3; NP_003326.2.
DR   UCSC; uc003cxr.4; human.
DR   AGR; HGNC:12471; -.
DR   CTD; 7318; -.
DR   DisGeNET; 7318; -.
DR   GeneCards; UBA7; -.
DR   HGNC; HGNC:12471; UBA7.
DR   HPA; ENSG00000182179; Low tissue specificity.
DR   MalaCards; UBA7; -.
DR   MIM; 191325; gene.
DR   neXtProt; NX_P41226; -.
DR   OpenTargets; ENSG00000182179; -.
DR   PharmGKB; PA162407761; -.
DR   VEuPathDB; HostDB:ENSG00000182179; -.
DR   eggNOG; KOG2012; Eukaryota.
DR   GeneTree; ENSGT00940000161447; -.
DR   HOGENOM; CLU_002556_0_0_1; -.
DR   InParanoid; P41226; -.
DR   OMA; FVSPMQT; -.
DR   OrthoDB; 10252231at2759; -.
DR   PAN-GO; P41226; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P41226; -.
DR   TreeFam; TF300586; -.
DR   PathwayCommons; P41226; -.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-5656169; Termination of translesion DNA synthesis.
DR   Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   Reactome; R-HSA-9909505; Modulation of host responses by IFN-stimulated genes.
DR   SignaLink; P41226; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 7318; 10 hits in 1161 CRISPR screens.
DR   ChiTaRS; UBA7; human.
DR   GeneWiki; UBE1L; -.
DR   GenomeRNAi; 7318; -.
DR   Pharos; P41226; Tbio.
DR   PRO; PR:P41226; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P41226; protein.
DR   Bgee; ENSG00000182179; Expressed in granulocyte and 98 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019782; F:ISG15 activating enzyme activity; IDA:HGNC-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; EXP:Reactome.
DR   GO; GO:0006974; P:DNA damage response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProt.
DR   GO; GO:0032020; P:ISG15-protein conjugation; IDA:HGNC-UCL.
DR   GO; GO:0019941; P:modification-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0036211; P:protein modification process; IDA:HGNC-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   CDD; cd01491; Ube1_repeat1; 1.
DR   CDD; cd01490; Ube1_repeat2; 1.
DR   FunFam; 1.10.10.2660:FF:000004; Ubiquitin activating enzyme 1; 1.
DR   FunFam; 2.40.30.180:FF:000001; ubiquitin-like modifier-activating enzyme 1; 1.
DR   FunFam; 3.50.50.80:FF:000001; ubiquitin-like modifier-activating enzyme 1; 1.
DR   FunFam; 3.10.290.60:FF:000005; Ubiquitin-like modifier-activating enzyme 7; 1.
DR   FunFam; 3.40.50.720:FF:000320; ubiquitin-like modifier-activating enzyme 7; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   Gene3D; 2.40.30.180; Ubiquitin-activating enzyme E1, FCCH domain; 1.
DR   Gene3D; 3.50.50.80; Ubiquitin-activating enzyme E1, inactive adenylation domain, subdomain 1; 1.
DR   Gene3D; 3.40.50.12550; Ubiquitin-activating enzyme E1, inactive adenylation domain, subdomain 2; 1.
DR   Gene3D; 1.10.10.2660; Ubiquitin-activating enzyme E1, SCCH domain; 1.
DR   Gene3D; 3.10.290.60; Ubiquitin-activating enzyme E1, UFD domain; 1.
DR   InterPro; IPR032420; E1_4HB.
DR   InterPro; IPR032418; E1_FCCH.
DR   InterPro; IPR042302; E1_FCCH_sf.
DR   InterPro; IPR045886; ThiF/MoeB/HesA.
DR   InterPro; IPR000594; ThiF_NAD_FAD-bd.
DR   InterPro; IPR018965; Ub-activating_enz_E1_C.
DR   InterPro; IPR042449; Ub-E1_IAD_1.
DR   InterPro; IPR038252; UBA_E1_C_sf.
DR   InterPro; IPR019572; UBA_E1_SCCH.
DR   InterPro; IPR042063; Ubi_acti_E1_SCCH.
DR   InterPro; IPR035985; Ubiquitin-activating_enz.
DR   InterPro; IPR018075; UBQ-activ_enz_E1.
DR   InterPro; IPR033127; UBQ-activ_enz_E1_Cys_AS.
DR   InterPro; IPR000011; UBQ/SUMO-activ_enz_E1-like.
DR   NCBIfam; TIGR01408; Ube1; 1.
DR   PANTHER; PTHR10953; UBIQUITIN-ACTIVATING ENZYME E1; 1.
DR   PANTHER; PTHR10953:SF143; UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 7; 1.
DR   Pfam; PF16191; E1_4HB; 1.
DR   Pfam; PF16190; E1_FCCH; 1.
DR   Pfam; PF09358; E1_UFD; 1.
DR   Pfam; PF00899; ThiF; 2.
DR   Pfam; PF10585; UBA_E1_SCCH; 1.
DR   PRINTS; PR01849; UBIQUITINACT.
DR   SMART; SM00985; UBA_e1_C; 1.
DR   SUPFAM; SSF69572; Activating enzymes of the ubiquitin-like proteins; 2.
DR   PROSITE; PS00865; UBIQUITIN_ACTIVAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cytoplasm; Direct protein sequencing;
KW   Host-virus interaction; Ligase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Repeat;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..1012
FT                   /note="Ubiquitin-like modifier-activating enzyme 7"
FT                   /id="PRO_0000194937"
FT   REPEAT          23..159
FT                   /note="1-1"
FT   REPEAT          423..575
FT                   /note="1-2"
FT   REGION          23..575
FT                   /note="2 approximate repeats"
FT   ACT_SITE        599
FT                   /note="Glycyl thioester intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10132"
FT   BINDING         442..471
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VARIANT         397..1012
FT                   /note="Missing (found in a small consanguineous family with
FT                   learning disability; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:28397838"
FT                   /id="VAR_080759"
FT   VARIANT         712
FT                   /note="P -> S (in dbSNP:rs11928913)"
FT                   /id="VAR_052434"
FT   VARIANT         817
FT                   /note="H -> R (in dbSNP:rs2230149)"
FT                   /id="VAR_047793"
FT   CONFLICT        355..378
FT                   /note="GVLSPMVAMLGAVAAQEVLKAISR -> RCLEPMVACWVSSCPGSAEGNLQ
FT                   (in Ref. 1; AAA75388 and 2; AAG49557)"
FT                   /evidence="ECO:0000305"
FT   HELIX           25..30
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          34..38
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           42..54
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          57..62
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           69..71
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            72..74
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           80..82
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:8SEA"
FT   HELIX           87..98
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          100..106
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           113..118
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          120..124
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           129..141
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          150..153
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          164..170
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          172..174
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          178..183
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          187..189
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   STRAND          191..194
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           198..202
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   TURN            218..222
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            232..234
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   STRAND          235..237
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   STRAND          247..250
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   STRAND          252..256
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          260..262
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           267..270
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           281..304
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           313..325
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          333..335
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           343..351
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          354..356
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           358..377
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          385..387
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           392..394
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          398..400
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   TURN            405..408
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           416..419
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           424..431
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          434..438
FT                   /evidence="ECO:0007829|PDB:8OIF"
FT   HELIX           442..454
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            455..457
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          459..461
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          463..467
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            474..476
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           477..479
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          481..483
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           485..487
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           492..503
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          509..512
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           518..520
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            521..524
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           526..529
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          535..537
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           542..555
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          559..565
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          568..574
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            576..578
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           586..592
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           598..600
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           608..623
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           625..630
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           632..636
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            640..644
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           645..652
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            654..656
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          667..670
FT                   /evidence="ECO:0007829|PDB:8SEA"
FT   HELIX           671..681
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           683..691
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          699..702
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          704..707
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   STRAND          719..721
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           723..739
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            747..749
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           751..755
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           761..764
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           765..769
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          770..773
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            778..782
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           783..797
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            813..816
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           817..831
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           839..843
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          845..848
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           854..873
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           878..880
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          883..887
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           888..890
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          892..896
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          904..906
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          909..911
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          917..920
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            922..925
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   HELIX           928..938
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          943..948
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          951..955
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          956..958
FT                   /evidence="ECO:0007829|PDB:8SV8"
FT   HELIX           960..966
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          967..970
FT                   /evidence="ECO:0007829|PDB:8OIF"
FT   HELIX           971..979
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   STRAND          989..996
FT                   /evidence="ECO:0007829|PDB:8SE9"
FT   TURN            1001..1003
FT                   /evidence="ECO:0007829|PDB:8WWX"
FT   STRAND          1008..1011
FT                   /evidence="ECO:0007829|PDB:8SE9"
SQ   SEQUENCE   1012 AA;  111694 MW;  A01E1106D81778EB CRC64;
     MDALDASKLL DEELYSRQLY VLGSPAMQRI QGARVLVSGL QGLGAEVAKN LVLMGVGSLT
     LHDPHPTCWS DLAAQFLLSE QDLERSRAEA SQELLAQLNR AVQVVVHTGD ITEDLLLDFQ
     VVVLTAAKLE EQLKVGTLCH KHGVCFLAAD TRGLVGQLFC DFGEDFTVQD PTEAEPLTAA
     IQHISQGSPG ILTLRKGANT HYFRDGDLVT FSGIEGMVEL NDCDPRSIHV REDGSLEIGD
     TTTFSRYLRG GAITEVKRPK TVRHKSLDTA LLQPHVVAQS SQEVHHAHCL HQAFCALHKF
     QHLHGRPPQP WDPVDAETVV GLARDLEPLK RTEEEPLEEP LDEALVRTVA LSSAGVLSPM
     VAMLGAVAAQ EVLKAISRKF MPLDQWLYFD ALDCLPEDGE LLPSPEDCAL RGSRYDGQIA
     VFGAGFQEKL RRQHYLLVGA GAIGCELLKV FALVGLGAGN SGGLTVVDMD HIERSNLSRQ
     FLFRSQDVGR PKAEVAAAAA RGLNPDLQVI PLTYPLDPTT EHIYGDNFFS RVDGVAAALD
     SFQARRYVAA RCTHYLKPLL EAGTSGTWGS ATVFMPHVTE AYRAPASAAA SEDAPYPVCT
     VRYFPSTAEH TLQWARHEFE ELFRLSAETI NHHQQAHTSL ADMDEPQTLT LLKPVLGVLR
     VRPQNWQDCV AWALGHWKLC FHYGIKQLLR HFPPNKVLED GTPFWSGPKQ CPQPLEFDTN
     QDTHLLYVLA AANLYAQMHG LPGSQDWTAL RELLKLLPQP DPQQMAPIFA SNLELASASA
     EFGPEQQKEL NKALEVWSVG PPLKPLMFEK DDDSNFHVDF VVAAASLRCQ NYGIPPVNRA
     QSKRIVGQII PAIATTTAAV AGLLGLELYK VVSGPRPRSA FRHSYLHLAE NYLIRYMPFA
     PAIQTFHHLK WTSWDRLKVP AGQPERTLES LLAHLQEQHG LRVRILLHGS ALLYAAGWSP
     EKQAQHLPLR VTELVQQLTG QAPAPGQRVL VLELSCEGDD EDTAFPPLHY EL
//
